{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T04:22:10Z","timestamp":1783138930309,"version":"3.54.6"},"reference-count":47,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019770","name":"Exploratory Research Center on Life and Living Systems, National Institutes of Natural Sciences","doi-asserted-by":"publisher","award":["21-101"],"award-info":[{"award-number":["21-101"]}],"id":[{"id":"10.13039\/501100019770","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP25ama121046"],"award-info":[{"award-number":["JP25ama121046"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP25gm0010010"],"award-info":[{"award-number":["JP25gm0010010"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.dmd.2026.100320","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T23:59:09Z","timestamp":1778284749000},"page":"100320","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["CYP3A5 polymorphism affects the disposition of tacrolimus and its metabolite in systemic circulation and peripheral tissues of mice introduced with the CYP3A5 gene"],"prefix":"10.1016","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2421-0532","authenticated-orcid":false,"given":"Genki","family":"Minegishi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-5861-4418","authenticated-orcid":false,"given":"Yuna","family":"Hiramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manami","family":"Sugahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1153-0720","authenticated-orcid":false,"given":"Satoshi","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Kazuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1514-8773","authenticated-orcid":false,"given":"Atsushi","family":"Miyajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Kazuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8105-6377","authenticated-orcid":false,"given":"Kaoru","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dmd.2026.100320_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.pharmtox.39.1.1","article-title":"Cytochrome P-450 3A4: regulation and role in drug metabolism","volume":"39","author":"Guengerich","year":"1999","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"5","key":"10.1016\/j.dmd.2026.100320_bib2","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s40262-013-0041-1","article-title":"Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations","volume":"52","author":"Ince","year":"2013","journal-title":"Clin Pharmacokinet"},{"issue":"5\u20136","key":"10.1016\/j.dmd.2026.100320_bib3","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/s41397-022-00288-2","article-title":"The genetic landscape of major drug metabolizing cytochrome P450 genes-an updated analysis of population-scale sequencing data","volume":"22","author":"Zhou","year":"2022","journal-title":"Pharmacogenomics J"},{"issue":"4","key":"10.1016\/j.dmd.2026.100320_bib4","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","article-title":"Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression","volume":"27","author":"Kuehl","year":"2001","journal-title":"Nat Genet"},{"issue":"3\u20134","key":"10.1016\/j.dmd.2026.100320_bib5","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.livres.2019.08.001","article-title":"Structural perspectives of the CYP3A family and their small molecule modulators in drug metabolism","volume":"3","author":"Wright","year":"2019","journal-title":"Liver Res"},{"issue":"1","key":"10.1016\/j.dmd.2026.100320_bib6","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/cpt.1596","article-title":"Quantitative prediction of CYP3A4- and CYP3A5-mediated drug interactions","volume":"107","author":"Guo","year":"2020","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.dmd.2026.100320_bib7","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1124\/dmd.105.008680","article-title":"Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro","volume":"34","author":"Dai","year":"2006","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100320_bib8","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1124\/jpet.106.118471","article-title":"Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes","volume":"321","author":"Dennison","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"10.1016\/j.dmd.2026.100320_bib9","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1124\/dmd.119.088823","article-title":"Interindividual variation in CYP3A activity influences lapatinib bioactivation","volume":"47","author":"Bissada","year":"2019","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmd.2026.100320_bib10","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt.113","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing","volume":"98","author":"Birdwell","year":"2015","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dmd.2026.100320_bib11","doi-asserted-by":"crossref","first-page":"111","DOI":"10.12659\/AOT.883229","article-title":"Tacrolimus-induced nephrotoxicity and genetic variability: a review","volume":"17","author":"Gijsen","year":"2012","journal-title":"Ann Transplant"},{"issue":"4","key":"10.1016\/j.dmd.2026.100320_bib12","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/FTD.0b013e3181e06818","article-title":"Tacrolimus dose requirements and CYP3A5 genotype and the development of calcineurin inhibitor-associated nephrotoxicity in renal allograft recipients","volume":"32","author":"Kuypers","year":"2010","journal-title":"Ther Drug Monit"},{"issue":"6","key":"10.1016\/j.dmd.2026.100320_bib13","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/clpt.2012.175","article-title":"Measurement and compartmental modeling of the effect of CYP3A5 gene variation on systemic and intrarenal tacrolimus disposition","volume":"92","author":"Zheng","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.dmd.2026.100320_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinthera.2017.05.045","article-title":"Effect of CYP3A4\u221722, CYP3A5\u22173, POR\u221728, and PPARA RS4253728 on tacrolimus exposure and neurotoxicity in kidney transplant recipients","volume":"39","author":"Woillard","year":"2017","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.dmd.2026.100320_bib15","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/00125480-199707000-00032","article-title":"Tacrolimus (FK506)-associated renal pathology","volume":"4","author":"Randhawa","year":"1997","journal-title":"Adv Anat Pathol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100320_bib16","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.tox.2007.10.022","article-title":"Drug metabolism enzyme expression and activity in primary cultures of human proximal tubular cells","volume":"244","author":"Lash","year":"2008","journal-title":"Toxicology"},{"issue":"12","key":"10.1016\/j.dmd.2026.100320_bib17","doi-asserted-by":"crossref","first-page":"9865","DOI":"10.1007\/s11033-020-05977-4","article-title":"Renal proximal tubular epithelial cells: review of isolation, characterization, and culturing techniques","volume":"47","author":"Mihevc","year":"2020","journal-title":"Mol Biol Rep"},{"issue":"3","key":"10.1016\/j.dmd.2026.100320_bib18","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/ndt\/gfac237","article-title":"Tacrolimus induces a pro-fibrotic response in donor-derived human proximal tubule cells dependent on common variants of the CYP3A5 and ABCB1 genes","volume":"38","author":"Knops","year":"2023","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.dmd.2026.100320_bib19","doi-asserted-by":"crossref","DOI":"10.12659\/AOT.936276","article-title":"Donor CYP3A5 expression decreases renal transplantation outcomes in White renal transplant recipients","volume":"27","author":"Warzyszy\u0144ska","year":"2022","journal-title":"Ann Transplant"},{"key":"10.1016\/j.dmd.2026.100320_bib20","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1124\/dmd.122.001060","article-title":"Process and system clearances in pharmacokinetic models: our basic clearance concepts are correct","volume":"51","author":"Korzekwa","year":"2023","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmd.2026.100320_bib21","article-title":"Probe drug T-1032 N-oxygenation mediated by cytochrome P450 3A5 in human hepatocytes in vitro and in humanized-liver mice in vivo","volume":"44","author":"Uehara","year":"2022","journal-title":"Drug Metab Pharmacokinet"},{"issue":"3","key":"10.1016\/j.dmd.2026.100320_bib22","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/hmg\/dds468","article-title":"Trans-chromosomic mice containing a human CYP3A cluster for prediction of xenobiotic metabolism in humans","volume":"22","author":"Kazuki","year":"2013","journal-title":"Hum Mol Genet"},{"issue":"8","key":"10.1016\/j.dmd.2026.100320_bib23","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1073\/pnas.1808255116","article-title":"Humanized UGT2 and CYP3A transchromosomic rats for improved prediction of human drug metabolism","volume":"116","author":"Kazuki","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.dmd.2026.100320_bib24","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-15033-0","article-title":"Modification of single-nucleotide polymorphism in a fully humanized CYP3A mouse by genome editing technology","volume":"7","author":"Abe","year":"2017","journal-title":"Sci Rep"},{"issue":"11","key":"10.1016\/j.dmd.2026.100320_bib25","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1124\/dmd.118.081216","article-title":"Characterization of P-glycoprotein humanized mice generated by chromosome engineering technology: its utility for prediction of drug distribution to the brain in humans","volume":"46","author":"Yamasaki","year":"2018","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmd.2026.100320_bib26","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1124\/dmd.122.001087","article-title":"Metabolic disposition of triazolam and clobazam in humanized CYP3A mice with a double-knockout background of mouse Cyp2c and Cyp3a genes","volume":"51","author":"Kobayashi","year":"2023","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmd.2026.100320_bib27","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1124\/dmd.113.054726","article-title":"Characterization of T-5 N-oxide formation as the first highly selective measure of CYP3A5 activity","volume":"42","author":"Li","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.dmd.2026.100320_bib28","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s11095-020-02921-w","article-title":"Pharmacokinetics and biodistribution of tacrolimus after topical administration: implications for vascularized composite allotransplantation","volume":"37","author":"Feturi","year":"2020","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.dmd.2026.100320_bib29","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/FTD.0b013e31824b0bfb","article-title":"Quantification of tacrolimus and three demethylated metabolites in human whole blood using LC-ESI-MS\/MS","volume":"34","author":"Dubbelboer","year":"2012","journal-title":"Ther Drug Monit"},{"issue":"1","key":"10.1016\/j.dmd.2026.100320_bib30","doi-asserted-by":"crossref","first-page":"33","DOI":"10.5458\/jag.jag.JAG-2022_0012","article-title":"Automatic calculation of the kinetic parameters of enzymatic reactions with their standard errors using Microsoft Excel","volume":"70","author":"Kitaoka","year":"2023","journal-title":"J Appl Glycosci (1999)"},{"issue":"7","key":"10.1016\/j.dmd.2026.100320_bib31","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1080\/00498254.2021.1921314","article-title":"In vivo evaluation of intestinal human CYP3A inhibition by macrolide antibiotics in CYP3A-humanised mice","volume":"51","author":"Minegishi","year":"2021","journal-title":"Xenobiotica"},{"issue":"3","key":"10.1016\/j.dmd.2026.100320_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.1197","article-title":"Induction of hepatic CYP3A4 expression by cholesterol and cholic acid: alterations of gene expression, microsomal activity, and pharmacokinetics","volume":"12","author":"Minegishi","year":"2024","journal-title":"Pharmacol Res Perspect"},{"issue":"1\u20132","key":"10.1016\/j.dmd.2026.100320_bib33","doi-asserted-by":"crossref","first-page":"305","DOI":"10.3109\/03602539409029800","article-title":"Cytochrome P450 in human fetal liver: significance and fetal-specific expression","volume":"26","author":"Kitada","year":"1994","journal-title":"Drug Metab Rev"},{"issue":"3","key":"10.1016\/j.dmd.2026.100320_bib34","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1165\/ajrcmb.16.3.9070608","article-title":"Expression and localization of CYP3A4 and CYP3A5 in human lung","volume":"16","author":"Anttila","year":"1997","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"11\u201312","key":"10.1016\/j.dmd.2026.100320_bib35","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/sj.bjc.6690292","article-title":"Cytochrome P450 CYP3A in human renal cell cancer","volume":"79","author":"Murray","year":"1999","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.dmd.2026.100320_bib36","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/aor.13551","article-title":"Tacrolimus: 20 years of use in adult kidney transplantation. What we should know about its nephrotoxicity","volume":"44","author":"Bentata","year":"2020","journal-title":"Artif Organs"},{"issue":"4","key":"10.1016\/j.dmd.2026.100320_bib37","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/FTD.0000000000000517","article-title":"Survival time to biopsy-proven acute rejection and tacrolimus adverse drug reactions in pediatric liver transplantation","volume":"40","author":"Riva","year":"2018","journal-title":"Ther Drug Monit"},{"issue":"1","key":"10.1016\/j.dmd.2026.100320_bib38","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0090-9556(25)06489-X","article-title":"Further metabolism of FK506 (tacrolimus). Identification and biological activities of the metabolites oxidized at multiple sites of FK506","volume":"23","author":"Iwasaki","year":"1995","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.dmd.2026.100320_bib39","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.pupt.2011.01.016","article-title":"Tacrolimus-induced pulmonary injury in rheumatoid arthritis patients","volume":"24","author":"Koike","year":"2011","journal-title":"Pulm Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dmd.2026.100320_bib40","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10067-015-2865-6","article-title":"Characteristic features of tacrolimus-induced lung disease in rheumatoid arthritis patients","volume":"35","author":"Sasaki","year":"2016","journal-title":"Clin Rheumatol"},{"issue":"34","key":"10.1016\/j.dmd.2026.100320_bib41","doi-asserted-by":"crossref","first-page":"24171","DOI":"10.1074\/jbc.M604507200","article-title":"Transforming growth factor beta1 induces hypoxia-inducible factor-1 stabilization through selective inhibition of PHD2 expression","volume":"281","author":"McMahon","year":"2006","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.dmd.2026.100320_bib42","doi-asserted-by":"crossref","first-page":"F898","DOI":"10.1152\/ajprenal.00335.2010","article-title":"Interdependence of HIF-1\u03b1 and TGF-\u03b2\/Smad3 signaling in normoxic and hypoxic renal epithelial cell collagen expression","volume":"300","author":"Basu","year":"2011","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"10.1016\/j.dmd.2026.100320_bib43","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1007\/s11033-024-09533-2","article-title":"Linagliptin ameliorates tacrolimus-induced renal injury: role of Nrf2\/HO-1 and HIF-1\u03b1\/CTGF\/PAI-1","volume":"51","author":"Nady","year":"2024","journal-title":"Mol Biol Rep"},{"issue":"13","key":"10.1016\/j.dmd.2026.100320_bib44","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1093\/emboj\/16.13.3866","article-title":"Mechanism of TGFbeta receptor inhibition by FKBP12","volume":"16","author":"Chen","year":"1997","journal-title":"EMBO J"},{"issue":"5","key":"10.1016\/j.dmd.2026.100320_bib45","doi-asserted-by":"crossref","first-page":"F433","DOI":"10.1152\/ajprenal.00226.2022","article-title":"Tacrolimus induces fibroblast-to-myofibroblast transition via a TGF-\u03b2-dependent mechanism to contribute to renal fibrosis","volume":"324","author":"Ume","year":"2023","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.dmd.2026.100320_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107438","article-title":"Revisiting the nature and pharmacodynamics of tacrolimus metabolites","volume":"209","author":"Mevizou","year":"2024","journal-title":"Pharmacol Res"},{"issue":"1","key":"10.1016\/j.dmd.2026.100320_bib47","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1006\/bbrc.1994.1947","article-title":"Interaction of tacrolimus(FK506) and its metabolites with FKBP and calcineurin","volume":"202","author":"Tamura","year":"1994","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955626000899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T04:12:08Z","timestamp":1783138328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955626000899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":47,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0090955626000899"],"URL":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100320","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CYP3A5 polymorphism affects the disposition of tacrolimus and its metabolite in systemic circulation and peripheral tissues of mice introduced with the CYP3A5 gene","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmd.2026.100320","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"100320"}}